Results of epidemiological analysis in the treatment of thyroid cancer 131I in the system of FMBA of Russia
Yu. A. Kaydash,
P. V. Sychev,
E. V. Mayakova,
E. L. Shaidiyarova,
I. A. Baryshnikov,
L. A. Arapova,
N. G. Chanchikova,
A. V. Belostotskiy https://doi.org/10.20340/vmi-rvz.2026.1.CLIN.10
Abstract
Purpose: to conduct a multifactorial comparative analysis of the effectiveness of different dosing regimes of radioiodine therapy in differentiated thyroid cancer (DTC) to identify dose-dependent patterns of tumor response to the therapy.
Materials and methods. The general population of the retrospective-prospective cohort study included 1615 cases during the follow-up period from 2023 to 2025. A multi-level statistical analysis of metastasis rates, disease progression, and the number of courses of radioiodine therapy at different doses of ¹³¹I was conducted.
Results. The personalized approach demonstrated a statistically significant improvement in the control of differentiated thyroid cancer: in the low-risk group, 0% progression at 3350±480 MBq (p<0.001), in the medium-risk group, 1.3% progression at 4750±800 MBq (p=0.003), and in the high-risk group, 4.4% progression at 8250±1250 MBq (p=0.012).
Conclusion. A comprehensive approach, including careful preparation of patients for radioiodine therapy, revision of histological reports if necessary, and a detailed analysis of diagnostic test results and previous post-therapeutic scans, can significantly improve the effectiveness of treatment. The data obtained from the epidemiological analysis serve as a basis for further research and the possibility of refining the national clinical guidelines for the personalized treatment of differentiated thyroid cancer using radioiodine therapy.
Keywords
thyroid cancer [D013964],
differentiated thyroid cancer [D013964],
radioiodine therapy [D007454],
iodine-131 [D007454],
radioiodine dosimetry [D011871],
metastasis [D009362],
disease progression [D018450],
personalized medicine [D057285],
epidemiological analysis [D004817],
risk stratification [D018570]
Supporting agencies: The work was carried out within the state assignment of the Russian Federal Medical and Biological Agency, registration number NIOKTR 1022060300090-7-3.2.21
About the Authors
Yu. A. Kaydash
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Yuliya A. Kaydash, Head of the Department of Radionuclide Therapy at the Nuclear Medicine Center, Radiologist
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
P. V. Sychev
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Petr V. Sychev, Head of the Nuclear Medicine Center, Radiologist
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
E. V. Mayakova
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Elena V. Mayakova, Chief Physician
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
E. L. Shaidiyarova
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Ekaterina L. Shaidiyarova, Oncologist of the Department of Radionuclide Therapy of the Nuclear Medicine Center
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
I. A. Baryshnikov
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Ivan A. Baryshnikov, Cand. Sci. (Med.), Head of the Department of Radionuclide Diagnostics at the Nuclear Medicine Center, X-ray and Radiological Specialist
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
L. A. Arapova
Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Larisa A. Arapova, Cand. Sci. (Med.), Head of the Nuclear Medicine Center, Deputy Chief Physician for Nuclear Medicine
Troitsky Ave., 115, Arkhangelsk, 163000, Russia
Competing Interests:
The authors declare no conflict of interest.
N. G. Chanchikova
Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency
Russian Federation
Competing Interests:
Russian Federation
Natal'ya G. Chanchikova, Director of the Nuclear Medicine Center, Radiologist
Kolomenskaya St., 26, Krasnoyarsk, 660037, Russia
Competing Interests:
The authors declare no conflict of interest.
A. V. Belostotskiy
Federal Scientific and Clinical Center of Medical Radiology and Oncology of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Andrey V. Belostotskiy, Dr. Sci. (Med.), Professor, Acting Director General
Kurchatov St., 5V, Dimitrovgrad, 433507, Russia
Competing Interests:
The authors declare no conflict of interest.
References
1. Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2024 godu. Pod red. A.D. Kaprina, V.V. Starinsko-go, A.O. Shakhzadovoy. Moskva: MNIOI im. P.A. Gertsena - filial FGBU «NMITS radiologii» Minzdrava Rossii. 2025:275. (In Russ).
2. Ito Y., Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocrin. J. 2008;13(8):337–341.
3. Caglar M., Tuncel M., Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin. Nucl. Med. 2002;27(11):767–771.
4. Garbuzov P.I., Drozdovsky B.Ya., Rodichev A.A., Timokhina O.V., Podolkhova N.V. Radioiodine Therapy for Thyroid Cancer. Practical Oncology. 2007;8(1):42-45. (In Russ).
5. Shurinov A.Yu., Borodavina E.V., Krylov V.V. et al. Guidelines for Radioiodine Therapy in Differentiated Thyroid Cancer and Post-Therapeutic Monitoring. Head and Neck Tumors. 2024;14(1):83–95. https://doi.org/10.17650/2222-1468-2024-14-1-83-95. (In Russ).
6. Klinicheskiye rekomendatsii MZ RF. Rak shchitovidnoy zhelezy. 2018. (In Russ).
Review
For citations:
Kaydash Yu.A., Sychev P.V., Mayakova E.V., Shaidiyarova E.L., Baryshnikov I.A., Arapova L.A., Chanchikova N.G., Belostotskiy A.V. Results of epidemiological analysis in the treatment of thyroid cancer 131I in the system of FMBA of Russia. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2026;16(1):101-106. (In Russ.) https://doi.org/10.20340/vmi-rvz.2026.1.CLIN.10
Views:
216
JATS XML
Email this article 
